Forte Biosciences, Inc.
General ticker "FBRX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.7B (TTM average)
Forte Biosciences, Inc. follows the US Stock Market performance with the rate: 28.7%.
Estimated limits based on current volatility of 9.2%: low 42.47$, high 51.02$
Factors to consider:
- Total employees count: 19 as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Insufficient capital, Clinical trial failure, Regulatory and compliance, Market competition, Labor/talent shortage/retention
- Current price 39.4% above estimated high
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [10.28$, 35.05$]
- 2026-12-31 to 2027-12-31 estimated range: [5.09$, 19.30$]
Financial Metrics affecting the FBRX estimates:
- Negative: with PPE of -5.7 at the end of fiscal year the price was high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 0.90 > -0.60
- Positive: Shareholder equity ratio, % of 73.68 > 64.23
- Negative: -0.75 < Inventory ratio change, % of 0
- Negative: negative Industry operating income (median)
Short-term FBRX quotes
Long-term FBRX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $32.49MM | $36.60MM | $70.66MM |
| Operating Income | $-32.49MM | $-36.60MM | $-70.66MM |
| Non-Operating Income | $1.01MM | $1.12MM | $2.32MM |
| R&D Expense | $21.86MM | $20.71MM | $57.65MM |
| Income(Loss) | $-31.48MM | $-35.48MM | $-68.34MM |
| Taxes | $0.00MM | $0.00MM | $1.04MM |
| Net Income(Loss)* | $-31.48MM | $-35.48MM | $-69.38MM |
| Stockholders Equity | $35.31MM | $52.48MM | $60.99MM |
| Assets | $38.98MM | $61.56MM | $82.78MM |
| Operating Cash Flow | $-28.71MM | $-30.75MM | $-50.88MM |
| Capital expenditure | $0.09MM | $0.04MM | $0.12MM |
| Investing Cash Flow | $0.05MM | $-35.99MM | $36.23MM |
| Financing Cash Flow | $24.68MM | $51.86MM | $69.36MM |
| Earnings Per Share** | $-24.92 | $-12.17 | $-0.47 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.